Skip to main content Deutsch


Marius Ozenil
Ing. Dr. Marius Ozenil, MSc

Department of Biomedical Imaging and Image-guided Therapy (Division of Nuclear Medicine)
Position: Research Associate (Postdoc)

ORCID: 0000-0001-6369-6613
T +43 1 40400 78350


Drug Evaluation, Preclinical; Positron-Emission Tomography; Radiochemistry

Research group(s)

Research interests

  • Radiochemical labeling of small molecules with medical radionuclides (especially 11C, 18F, 68Ga, 177Lu)
  • Implementation of tracer production for in-house use.
  • Development of novel radiolabeling methods using [11C]CO2-fixation chemistry.
  • Chemical synthesis of stable precursors for radiolabeling
  • In vitro preclinical evaluation of potential PET tracers (e.g. parameters like receptor binding affinity, ligand receptor kinetics, lipophilicity, plasma protein binding and metabolic stability)
  • Structures of special interest: bile acids, PARP inhibitors, muscarinic acetylcholine receptor ligands

Techniques, methods & infrastructure

  • Labs for handling open radioactivity (hot cells, radiosynthesis modules)
  • Radiochemistry of PET nuclides (especially 11C, 18F) provided by the AKH cyclotron
  • Organic synthetic chemistry
  • Analytical chemistry and structure identification (NMR, MS and other spectroscopic methods), chromatography (especially various HPLCs)
  • Radioligand binding assays

Selected publications

  1. Ozenil, M. et al., 2020. Enhanced arecoline derivatives as muscarinic acetylcholine receptor M1 ligands for potential application as PET radiotracers. European Journal of Medicinal Chemistry, 204, p.112623. Available at:
  2. Ozenil, M. et al., 2020. Synthesis, Biological, and Computational Evaluation of Antagonistic, Chiral Hydrobenzoin Esters of Arecaidine Targeting mAChR M1. Pharmaceuticals, 13(12), p.437. Available at:
  3. Ozenil, M. et al. (2021) ‘Unexpected scaffold rearrangement product of pirenzepine found in commercial samples’, Scientific Reports, 11(1). Available at: